| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 5. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | solifenacin/tamsulosin (Vesomni®) |
| Formulation | 6 mg/0.4 mg modified-release tablet |
| Reference number | 1105 |
| Indication | The treatment of moderate to severe storage symptoms (urgency, increased micturition frequency) and voiding symptoms associated with benign prostatic hyperplasia (BPH) in men who are not adequately responding to treatment with monotherapy |
| Company | Astellas Pharma Ltd |
| BNF chapter | Obstetrics, gynaecology & urinary tract disorders |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 15/10/2013 |